Loading clinical trials...
Loading clinical trials...
Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age
Conditions
Interventions
Besivance
Gatifloxacin
Locations
1
United States
Bausch & Lomb Incorporated
Bridgewater, New Jersey, United States
Start Date
May 1, 2011
Primary Completion Date
January 1, 2013
Completion Date
October 1, 2013
Last Updated
September 3, 2014
NCT02432807
NCT00347932
NCT01238783
Lead Sponsor
Bausch & Lomb Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions